AcuraStem Inc

AcuraStem Inc has raised $5.0M in total funding. The most recent round was Seed.

AcuraStem Inc is headquartered in Pasadena, CA.

Drugs for neurodegenerative diseases like ALS often fail in clinical trials because over-reliance on animal models gives a poor understanding of the real human disease mechanisms.

AcuraStem is a patient-based biotech company that models neurodegenerative diseases (sporadic ALS, FTD) using individual patient cells to develop treatments, including its lead candidate AS-241.

They point to their proprietary iNeuroRx® disease-modeling platform, described as the "gold standard," and to external validation such as a $7.5 million CIRM grant to advance AS-241 toward first-in-human trials.

Co-founded by CEO Sam Alworth and Dr. Qing Liu; this ALS/FTD biotech was awarded $7.5M in grant funding from California's stem cell agency (CIRM) toward its first human trial, on top of earlier NIH and DOD funding.